The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
Open accessAbstract
Tumors escape immunological rejection by a diversity of mechanisms. In this report, we demonstrate that the colon cancer cell SW620 expresses functional Fas ligand (FasL), the triggering agent of Fas receptor (FasR)-mediated apoptosis within the immune system. FasL mRNA and cell surface FasL were detected in SW620 cells using reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemical staining, respectively. We show that SW620 kills Jurkat T cells in a Fas-mediated manner. FasR-specific antisense oligonucleotide treatment, which transiently inhibited FasR expression, completely protected Jurkat cells from killing by SW620. FasL-specific antisense oligonucleotide treatment of SW620 inhibited its Jurkat-killing activity. FasL has recently been established as a mediator of immune privilege in mouse retina and testis. Our finding that colon cancer cells express functional FasL suggests it may play an analogous role in bestowing immune privilege on human tumors. HT29 and SW620 colon cancer cells were found to express FasR mRNA and cell surface FasR using RT-PCR and immunofluorescence flow cytometry, respectively. However, neither of these cells underwent apoptosis after treatment by the anti-FasR agonistic monoclonal antibody CH11. Our results therefore suggest a Fas counterattack model for immune escape in colon cancer, whereby the cancer cells resist Fas-mediated T cell cytotoxicity but express functional FasL, an apoptotic death signal to which activated T cells are inherently sensitive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S.-I., Sameshima, M., Hase, A., Seto, Y., & Nagata, S. (1991) · Cell · doi:10.1016/0092-8674(91)90614-5 · Cited by 2,737
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 2,005
Fisher, G. H., Rosenberg, F. J., Straus, S. E., Dale, J. K., Middelton, L. A., Lin, A. Y., Strober, W., Lenardo, M. J., & Puck, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90013-6 · Cited by 1,465
Mutations in Fas Associated with Human Lymphoproliferative Syndrome and Autoimmunity
Rieux-Laucat, F., Le Deist, F., Hivroz, C., Roberts, I. A. G., Debatin, K. M., Fischer, A., & de Villartay, J. P. (1995) · Science · doi:10.1126/science.7539157 · Cited by 1,297
A role for CD95 ligand in preventing graft rejection
Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., & Duke, R. C. (1995) · Nature · doi:10.1038/377630a0 · Cited by 1,155
Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule
Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J., & Mountz, J. D. (1994) · Science · doi:10.1126/science.7510905 · Cited by 1,107
Fas ligand mediates activation-induced cell death in human T lymphocytes.
Alderson, M. R., Tough, T. W., Davis-Smith, T., Braddy, S., Falk, B., Schooley, K. A., Goodwin, R. G., Smith, C. A., Ramsdell, F., & Lynch, D. H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.71 · Cited by 934
Fas and Fas ligand: lpr and gld mutations
Nagata, S., & Suda, T. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80069-7 · Cited by 892
Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression
Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W.-W., Kruzel, E., et al. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3032 · Cited by 734
Cited by
Cell Membrane Coating Nanotechnology
Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018) · Advanced Materials · doi:10.1002/adma.201706759 · Cited by 1,885
Role of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404
Jass, J. R. (2007) · Histopathology · doi:10.1111/j.1365-2559.2006.02549.x · Cited by 1,384
Reed, J. C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64779-7 · Cited by 1,288
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Dysregulation of Apoptosis in Cancer
Reed, J. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2941 · Cited by 987
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878
“Constitutive CD95L expression has also been shown for melanoma (65), lung cancer (66), and colon cancer (67).”
Nagata, S. (1999) · Annual Review of Genetics · doi:10.1146/annurev.genet.33.1.29 · Cited by 779
Does the Immune System See Tumors as Foreign or Self?
Pardoll, D. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141135 · Cited by 753
Mesenchymal stem cells avoid allogeneic rejection
Ryan, J. M., Barry, F. P., Murphy, J. M., & Mahon, B. P. (2005) · Journal of Inflammation · doi:10.1186/1476-9255-2-8 · Cited by 714
NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway
Terabe, M., Matsui, S., Noben-Trauth, N., Chen, H., Watson, C., Donaldson, D. D., Carbone, D. P., Paul, W. E., & Berzofsky, J. A. (2000) · Nature Immunology · doi:10.1038/82771 · Cited by 699
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061283 · Cited by 531
Huber, V., Fais, S., Iero, M., Lugini, L., Canese, P., Squarcina, P., Zaccheddu, A., Colone, M., Arancia, G., Gentile, M., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.045 · Cited by 524
Death receptors in chemotherapy and cancer
Debatin, K.-M., & Krammer, P. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207558 · Cited by 505
The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond
Dostert, C., Grusdat, M., Letellier, E., & Brenner, D. (2019) · Physiological Reviews · doi:10.1152/physrev.00045.2017 · Cited by 498
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Natural Killer Cells and Cancer
(2003) · Advances in Cancer Research · doi:10.1016/s0065-230x(03)90004-2 · Cited by 438
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
Saas, P., Walker, P. R., Hahne, M., Quiquerez, A. L., Schnuriger, V, Perrin, G., French, L., Van Meir, E. G., de Tribolet, N., Tschopp, J., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119273 · Cited by 398
CD95(APO-1/Fas)-Mediated Apoptosis: Live and Let Die
Krammer, P. H. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60402-2 · Cited by 394
Regulation of the Proinflammatory Effects of Fas Ligand (CD95L)
Chen, J.-J., Sun, Y., & Nabel, G. J. (1998) · Science · doi:10.1126/science.282.5394.1714 · Cited by 383
Mechanisms of apoptosis avoidance in cancer
Reed, J. C. (1999) · Current Opinion in Oncology · doi:10.1097/00001622-199901000-00014 · Cited by 374
Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand
Miwa, K., Asano, M., Horai, R., Iwakura, Y., Nagata, S., & Suda, T. (1998) · Nature Medicine · doi:10.1038/3276 · Cited by 373
Hematologic consequences of exposure to ionizing radiation
Dainiak, N. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00802-0 · Cited by 362
The role of CD95 and CD95 ligand in cancer
Peter, M. E., Hadji, A., Murmann, A. E., Brockway, S., Putzbach, W., Pattanayak, A., & Ceppi, P. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.3 · Cited by 357
The host—tumor immune conflict: from immunosuppression to resistance and destruction
Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A., & Blay, J. Y. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01115-8 · Cited by 350
Bennett, M. W., O’Connell, J., O’Sullivan, G. C., Brady, C., Roche, D., Collins, J. K., & Shanahan, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.11.5669 · Cited by 326
Self-citationImmune defects observed in patients with primary malignant brain tumors
Dix, A. R., Brooks, W. H., Roszman, T. L., & Morford, L. A. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00203-9 · Cited by 323
Cell death induced by the Fas/Fas ligand pathway and its role in pathology
Waring, P., & Müllbacher, A. (1999) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1999.00837.x · Cited by 322
Autoimmune thyroid disease: new models of cell death in autoimmunity
Stassi, G., & De Maria, R. (2002) · Nature Reviews Immunology · doi:10.1038/nri750 · Cited by 284
Sensitization of Cancer Cells Treated With Cytotoxic Drugs to Fas-Mediated Cytotoxicity
Micheau, O., Solary, E., Hammann, A., Martin, F., & Dimanche-Boitrel, M.-T. (1997) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/89.11.783 · Cited by 281
Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K. J., & Takahashi, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6420 · Cited by 252
The Fas counterattack: Cancer as a site of immune privilege
O’Connell, J., Bennett, M. W., O’Sullivan, G. C., Collins, J. K., & Shanahan, F. (1999) · Immunology Today · doi:10.1016/s0167-5699(98)01382-6 · Cited by 232
Self-citationUckan, D. (1997) · Molecular Human Reproduction · doi:10.1093/molehr/3.8.655 · Cited by 206
Bacteria as vectors for gene therapy of cancer
Baban, C. K., Cronin, M., O’Hanlon, D., O’Sullivan, G. C., & Tangney, M. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.6.13146 · Cited by 175
Self-citationGlioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70
Chahlavi, A., Rayman, P., Richmond, A. L., Biswas, K., Zhang, R., Vogelbaum, M., Tannenbaum, C., Barnett, G., & Finke, J. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4395 · Cited by 141
Immune Escape for Renal Cell Carcinoma: CD70 Mediates Apoptosis in Lymphocytes
Diegmann, J., Junker, K., Loncarevic, I. F., Michel, S., Schimmel, B., & von Eagelinq, F. (2006) · Neoplasia · doi:10.1593/neo.06451 · Cited by 92
Loss of Fas-Ligand Expression in Mouse Keratinocytes during UV Carcinogenesis
Ouhtit, A., Gorny, A., Muller, H. K., Hill, L. L., Owen-Schaub, L., & Ananthaswamy, H. N. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64836-5 · Cited by 82
Gray, C. P., Franco, A. V., Arosio, P., & Hersey, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1269 · Cited by 70
Rethinking liquid biopsy: Microfluidic assays for mobile tumor cells in human body fluids
Neoh, K. H., Hassan, A. A., Chen, A., Sun, Y., Liu, P., Xu, K.-F., Wong, A. S. T., & Han, R. P. S. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.006 · Cited by 44
Metadata
- Authors
- O'Connell, J., O'Sullivan, G. C., Collins, J. K., & Shanahan, F.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1996-09-01
- Volume
- 184
- Issue
- 3
- Pages
- 1075-1082
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2168747001
- Cited by
- 878
- References
- 35
- FWCI
- 28.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.